日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級(jí)生物類似抗體
  4. CD274 (Lodapolimab Biosimilar) Recombinant Monoclonal Antibody

CD274 (Lodapolimab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號(hào)：
    CSB-RA878942MB11HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CD274(Lodapolimab Biosimilar Antibody)重組單克隆抗體是一種針對(duì)CD274靶點(diǎn)的生物制劑，主要用于生命科學(xué)研究領(lǐng)域。該抗體通過重組DNA技術(shù)制備，具有高特異性和親和力，能夠精準(zhǔn)識(shí)別并結(jié)合CD274分子，為相關(guān)機(jī)制研究提供可靠工具。 在科研應(yīng)用中，CD274重組單克隆抗體可用于多種實(shí)驗(yàn)場景。例如，在細(xì)胞水平研究中，可通過檢測細(xì)胞表面CD274的表達(dá)水平，或利用技術(shù)觀察其在組織中的分布情況。在分子機(jī)制探討方面，該抗體能助力研究CD274相關(guān)信號(hào)通路，為深入理解其在生理和病理過程中的作用提供支持。 該抗體采用先進(jìn)的重組表達(dá)系統(tǒng)生產(chǎn)，確保了批次間的穩(wěn)定性和一致性，適合長期實(shí)驗(yàn)研究使用。其高純度的特性可有效減少非特異性結(jié)合，提高實(shí)驗(yàn)結(jié)果的可靠性。研究人員可根據(jù)具體實(shí)驗(yàn)需求，將其應(yīng)用于細(xì)胞功能分析等多種實(shí)驗(yàn)方法中。 作為科研工具，CD274重組單克隆抗體為探索CD274相關(guān)的生物學(xué)過程、疾病機(jī)制以及潛在治療靶點(diǎn)提供了重要支持，有助于推動(dòng)免疫學(xué)、腫瘤學(xué)等領(lǐng)域的基礎(chǔ)研究和應(yīng)用研究發(fā)展。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Anti-PD-L1 checkpoint antibody research-grade biosimilar; Lodapolimab (USAN) research-grade biosimilar; LY-3300054 research-grade biosimilar ;CD274 antibody; B7H1 antibody; PDCD1L1 antibody; PDCD1LG1 antibody; PDL1 antibody; Programmed cell death 1 ligand 1 antibody; PD-L1 antibody; PDCD1 ligand 1 antibody; Programmed death ligand 1 antibody; hPD-L1 antibody; B7 homolog 1 antibody; B7-H1 antibody; CD antigen CD274 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human CD274 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
  • 基因功能參考文獻(xiàn)：
    1. an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1 causing T cell exhaustion PMID: 29593314
    2. hypothesized that an oncolytic poxvirus would attract T cells into the tumour, and induce PD-L1 expression in cancer and immune cells, leading to more susceptible targets for anti-PD-L1 immunotherapy PMID: 28345650
    3. multivariate Cox hazards regression analysis identified ALCAM and PD-L1 (both P < 0.01) as potential independent risk factors for primary diffuse pleural mesotheliomas PMID: 28811252
    4. miR-191-5p was identified to have negative correlation with PD-L1 expression and acted as an independent prognostic factor of OS in patients with colon adenocarcinoma. PMID: 30045644
    5. our findings suggest a regulatory mechanism of PD-L1 through data analysis, in vitro and vivo experiments, which is an important factor of immune evasion in GC cells, and CXCL9/10/11-CXCR3 could regulate PD-L1 expression through STAT and PI3K-Akt signaling pathways in GC cells. PMID: 29690901
    6. CD163(+)CD204(+) Tumor-associated macrophages possibly play a key role in the invasion and metastasis of oral squamous cell carcinoma by T-cell regulation via IL-10 and PD-L1 production. PMID: 28496107
    7. Results demonstrated that the expression of PDL1 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. Blocking PDL1 can inhibit tumor growth by activating CD4+ and CD8+ T cells involved in the immune response. PMID: 30272332
    8. miR-574-3p was identified to potentially regulate PD-L1 expression in chordoma, which inversely correlated with PD-L1. Positive PD-L1 expression on tumor cells was associated with advanced stages and TILs infiltration, whereas decreased miR-574-3p level correlated with higher muscle invasion, more severe tumor necrosis and poor patient survival. PMID: 29051990
    9. PD-L1 expression was detected in 69% of cases of primary melanoma of the vulva PMID: 28914674
    10. PD-L1 tumor cell expression is strongly associated with increased HIF-2alpha expression and presence of dense lymphocytic infiltration in clear cell renal cell carcinoma. PMID: 30144808
    11. Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma PMID: 30454551
    12. PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer PMID: 28782638
    13. Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma PMID: 30050132
    14. Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas PMID: 29122656
    15. Positive PD-L1 expression is indicative of worse clinical outcome in Xp11.2 renal cell carcinoma. PMID: 28522811
    16. PD-L1 expression in cancer cells is upregulated in response to DNA double-strand break. PMID: 29170499
    17. Targeting PD-L1 Protein is an efficient anti-cancer immunotherapy strategy. (Review) PMID: 30264678
    18. Suggest that PD-L1 may play a relevant role in metastatic spread and may be a candidate prognostic biomarker in cutaneous squamous cell carcinoma. PMID: 29742559
    19. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PMID: 29874226
    20. SLC18A1 might complement other biomarkers currently under study in relation to programmed cell death protein 1/programmed cell death protein ligand 1 inhibition PMID: 30194079
    21. Low PDL1 expression is associated with mammary and extra-mammary Paget disease. PMID: 29943071
    22. Low PDL1 mRNA expression is associated with non-muscle-invasive bladder cancer. PMID: 29150702
    23. we found that in advanced stage NSCLC patients who received nivolumab, the C allele of PD-L1 rs4143815 and the G allele of rs2282055 were significantly associated with better ORR and PFS. This is the first report that PD-L1 SNP, which was thought to increase PD-L1 expression, is associated with a response to nivolumab. PMID: 28332580
    24. PD-L1 expression differs between the two components of lung ASCs. Given the complexity of lung ASCs, their treatment outcomes may be improved by administration of both EGFR TKIs and anti-PD-1/PD-L1 antibodies in cases where EGFR mutations are present and PD-L1 is overexpressed. PMID: 28387300
    25. IDO and B7-H1 expressions were observed in patients with pancreatic carcinoma tissues and are important markers for PC malignant progression PMID: 30029936
    26. There was higher programmed cell death protein ligand-1(PD-L1) expression in post-treatment EBV DNA-positive patients. Post-treatment positive EBV DNA status maybe a useful biomarker of worse outcomes in early stage -stage extranodal natural killer/T cell lymphoma. PMID: 30116872
    27. PD-L1 is a critical TTP-regulated factor that contributes to inhibiting antitumor immunity. PMID: 29936792
    28. Structural and functional analyses unexpectedly reveal an N-terminal loop outside the IgV domain of PD-1. This loop is not involved in recognition of PD-L1 but dominates binding to nivolumab, whereas N-glycosylation is not involved in binding at all. PMID: 28165004
    29. While mutational analysis appeared similar to that of older patients with OCSCC who lack a smoking history, a comparatively high degree of PD-L1 expression and PD-1/L1 concordance (P=0.001) was found among young female OCSCC patients. PMID: 28969885
    30. PD-L1 expression is predictive of survival in diffuse large B-cell lymphoma, irrespective of rituximab treatment. PMID: 29748856
    31. PD-L1 expression was augmented on CD8+ T cells in BALF of a patient with smoldering adult T-cell lymphoma and Pneumocystis jiroveci pneumonia. This suggested that the PD-1-PD-L1 system may suppress not only antitumor immunity but also host defense against pathogens and thereby allow establishment of chronic HTLV-1 infection and immunodeficiency. PMID: 28967040
    32. MUC1 drives PD-L1 expression in triple-negative breast cancer cells. PMID: 29263152
    33. Positive PD-L1 expression was found in 36.8% of inflammatory breast carcinoma (IBC) samples but was not significantly associated with the clinicopathologic variables examined. Worse overall survival (OS) was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative. PMID: 29425258
    34. PD-L1 expression display a highly variable distribution in clear cell renal cell carcinomas and this particularity should be kept in mind when selecting the tumor samples to be tested for immunotherapy. PMID: 29661736
    35. Report relatively low level PD-L1 positivity in treatment-naive acinar prostatic adenocarcinoma. PMID: 30257853
    36. High PD-L1 expression is associated with pulmonary metastases in head and neck squamous cell carcinoma. PMID: 29937180
    37. these data suggest that DNA-damage signaling is insufficient for upregulating PD-L1 in normal human dermal fibroblasts PMID: 29859207
    38. High CD274 expression is associated with Oral Squamous Cell Carcinoma. PMID: 28669079
    39. This study provides important evidence of higher levels of agreement of PD-L1 expression in pulmonary metastasis compared with in multiple primary lung cancer, and high positivity of PD-L1 expression in pulmonary metastatic lesions with wild-type EGFR in an Asian population. PMID: 29254651
    40. High PD-L1 expression is associated with Mycobacterium avium complex-induced lung disease. PMID: 28169347
    41. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in metastatic breast cancer PMID: 29063313
    42. The expression of PDL1 was significantly increased following treatment with gefitinib. PMID: 29901173
    43. These results demonstrated that the IFNGinduced immunosuppressive properties of B7H1 in human BM and WJMSCs were mediated by STAT1 signaling, and not by PI3K/RACalpha serine/threonineprotein kinase signaling PMID: 29901104
    44. PD-1/PD-L1 expression is a frequent occurrence in poorly differentiated neuroendocrine carcinomas of the digestive system. PMID: 29037958
    45. High CD274 expression is associated with Epithelial Ovarian Cancer. PMID: 30275195
    46. Studied expression levels of CD274 molecule (PD-L1) in thymic epithelial tumors. Found PD-L1 expression level correlated with the degree of TET malignancy. PMID: 29850538
    47. Authors assessed PD-L1 expression in both tumor cells and tumor-infiltrating immune cells in the tumor specimens (complete histological sections, not tissue microarray). PMID: 28420659
    48. We conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors, expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling PMID: 29843813
    49. PD-L1 expression is a prognostic factor related with poor survival among patients that developed non-small cell lung cancer. PMID: 29614306
    50. The inhibition of PTEN also reduced the cancer effects of CD4+ T cells on non-small cell lung cancer (NSCLC) cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4+ T cells in human NSCLC through PD-L1 expression via the PTEN pathway. PMID: 29767245

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Endomembrane system; Single-pass type I membrane protein.
  • 蛋白家族：
    Immunoglobulin superfamily, BTN/MOG family
  • 組織特異性：
    Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 17635

    OMIM: 605402

    KEGG: hsa:29126

    STRING: 9606.ENSP00000370989

    UniGene: Hs.521989



×
生命科學(xué)計(jì)算平臺(tái)